Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

731
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
731
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Vaccines01:30

Cancer Vaccines

562
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leniolisib: First Approval.

Drugs·2023
Same author

Correction to: Durvalumab: A Review in Extensive-Stage SCLC.

Targeted oncology·2021
Same author

Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.

Drugs·2021
Same author

Imlifidase: First Approval.

Drugs·2020
Same author

Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

Clinical drug investigation·2019
Same author

Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Drugs·2019
Same journal

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same journal

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.

Targeted oncology·2026
Same journal

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.

Targeted oncology·2026
Same journal

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Targeted oncology·2026
Same journal

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Targeted oncology·2026
Same journal

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Targeted oncology·2026
See all related articles

Related Experiment Video

Updated: Oct 14, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K

Durvalumab: A Review in Extensive-Stage SCLC.

Zaina T Al-Salama1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.

Targeted Oncology
|November 3, 2021
PubMed
Summary
This summary is machine-generated.

Durvalumab plus chemotherapy significantly improves overall survival and progression-free survival for extensive-stage small cell lung cancer (ES-SCLC) patients. This combination therapy offers a valuable and accepted standard of care option for first-line treatment.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Related Experiment Videos

Last Updated: Oct 14, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Extensive-stage small cell lung cancer (ES-SCLC) has limited first-line treatment options.
  • Programmed cell death-ligand 1 (PD-L1) is a target for cancer immunotherapy.
  • Durvalumab is a monoclonal antibody targeting PD-L1.

Purpose of the Study:

  • To evaluate the efficacy and safety of durvalumab in combination with chemotherapy for first-line treatment of ES-SCLC.
  • To compare durvalumab plus chemotherapy versus chemotherapy alone in the CASPIAN trial.

Main Methods:

  • Phase III randomized controlled trial (CASPIAN trial).
  • Patients received durvalumab with etoposide and either carboplatin or cisplatin, followed by maintenance durvalumab, or chemotherapy alone.
  • Assessed overall survival, progression-free survival, and objective response rates.

Main Results:

  • Durvalumab combination therapy demonstrated significantly longer overall survival compared to chemotherapy alone.
  • A favorable hazard ratio for progression-free survival was observed with durvalumab plus chemotherapy.
  • Higher objective response rates were achieved in the durvalumab combination arm.

Conclusions:

  • Durvalumab in combination with etoposide and platinum-based chemotherapy is an effective first-line treatment for ES-SCLC.
  • The combination therapy shows a manageable tolerability profile.
  • Durvalumab plus chemotherapy is a valuable treatment option and an accepted standard of care for ES-SCLC.